Combination of IL-12 gene therapy and CTX chemotherapy inhibits growth of primary B16(F10) melanoma tumors in mice

• Authors: Iwona Mitrus , Klaudia Delić , Natalia Wróbel , Ewa Missol-Kolka , Stanisław Szala
• Languages of publication: EN

Abstracts

EN

We investigated suppression of murine B16(F10) melanoma tumor growth following a therapy which involved concomitant administration of cyclophosphamide and plasmid DNA bearing interleukin-12 gene. Since both therapeutic factors display antiangiogenic capabilities, we assumed that their use in blocking the formation of new blood vessels would result in augmented inhibition of tumor growth. This combined therapy regimen indeed resulted in a considerable suppression of tumor growth. We observed a statistically significant extension of treated animals' lifespan. Interestingly, the therapeutic effect was also obtained using a plasmid without an interleukin gene insert. This observation suggests that plasmid DNA, which has been widely applied for treating neoplastic tumors, contains element(s) that elicit immune response in mice.

Keywords

EN

antiangiogenic therapy; interleukin-12 gene; combined therapy

• Publisher: Polish Biochemical Society
• Journal: Acta Biochimica Polonica
• Year: 2006
• Volume: 53
• Issue: 2
• Pages: 357-360

Dates

published

2006

received

2005-03-22

revised

2005-10-05

accepted

2005-10-25

(unknown)

2006-05-29

Contributors

author

Iwona Mitrus

• Department of Molecular Biology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

author

Klaudia Delić

• Department of Molecular Biology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

author

Natalia Wróbel

• Department of Molecular Biology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

author

Ewa Missol-Kolka

• Department of Molecular Biology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

author

Stanisław Szala

• Department of Molecular Biology, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland

References

• Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60: 1878-1886.
• Budryk M, Wilczynska U, Szary J, Szala S (2000) Direct transfer of IL-12 gene into growing Renca tumors. Acta Biochim Polon 47: 385-391.
• Carpentier AF, Auf G, Delattre JY (2003) CpG-oligonucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Front Biosci 8: e115-127.
• Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186.
• Hendrzak JA, Brunda MJ (1995) Interleukin-12. Biologic activity, therapeutic utility, and role in disease. Lab Invest 72: 619-637.
• Indraccolo S (2004) Undermining tumor angiogenesis by gene therapy: an emerging field. Curr Gene Ther 4: 297-308.
• Kerbel RS, Kamen BA (2004) The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4: 423-436.
• Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G (2002) Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 5: 237-256.
• Shi F, Rakhmilevich AL, Heise CP, Oshikawa K, Sondel PM, Yang NS, Mahvi DM (2002) Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine model. Mol Cancer Ther 1: 949-957.
• Sivridis E, Giatromanolaki A, Koukourakis MI (2003) The vascular network of tumours - what is it not for? J Pathol 201: 173-180.
• Tandle A, Blazer DG 3rd, Libutti SK (2004) Antiangiogenic gene therapy of cancer: recent developments. J Transl Med 2: 22-41.